We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $0.59, demonstrating a +2.23% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.17%. Elsewhere, the Dow lost 0.18%, while the tech-heavy Nasdaq added 0.4%.
Coming into today, shares of the company had lost 15.6% in the past month. In that same time, the Medical sector gained 0.65%, while the S&P 500 lost 1.29%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$0.09, up 35.71% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.4 per share and revenue of $4.05 million, indicating changes of -53.85% and +98.48%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Humacyte, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 161, this industry ranks in the bottom 35% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $0.59, demonstrating a +2.23% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.17%. Elsewhere, the Dow lost 0.18%, while the tech-heavy Nasdaq added 0.4%.
Coming into today, shares of the company had lost 15.6% in the past month. In that same time, the Medical sector gained 0.65%, while the S&P 500 lost 1.29%.
Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$0.09, up 35.71% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.4 per share and revenue of $4.05 million, indicating changes of -53.85% and +98.48%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Humacyte, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 161, this industry ranks in the bottom 35% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.